Solara Active Pharma Sciences Financial Results
- Market cap
- ₹3,120 crore
- P/E
- 22.5
- P/B
- 2.85
- ROE
- 14.5%
- Dividend yield
- 1.20%
- 52-week range
- ₹466.34 – ₹874.40
In the Q1 quarter, Solara Active Pharma Sciences reported revenue of ₹250 crore, and net profit of ₹28.08 crore. The operating margin was 19%. Earnings per share were ₹28.79.
Summary
Solara Active Pharma Sciences Limited is showing strong operational fundamentals with healthy volume activity and bullish technical indicators.
AI-generated summary of public data — not investment advice · 9 October 2026
Solara Active Pharma Sciences quarterly results
Consolidated figures, newest quarter first.
| Item | Q1 |
|---|---|
| Revenue | 250 |
| Expenses | 203 |
| Operating profit | 46.8 |
| Operating margin % | 19% |
| Other income | 45 |
| Interest | 12 |
| Depreciation | 35 |
| Profit before tax | 37.44 |
| Tax % | 25% |
| Net profit | 28.08 |
| EPS (₹) | 28.79 |
Solara Active Pharma Sciences annual profit and loss
Financial years, newest first. TTM = trailing twelve months.
| Item | FY25 |
|---|---|
| Revenue | 1,092 |
| Expenses | 874 |
| Operating profit | 218 |
| Operating margin % | 20% |
| Other income | 180 |
| Interest | 50 |
| Depreciation | 140 |
| Profit before tax | 172 |
| Tax % | 25% |
| Net profit | 128 |
| EPS (₹) | 115.15 |
| Dividend payout % | 22% |
Source: Company filings (consolidated), in ₹ crore. Data as of 9 October 2026. How this data is compiled.
Solara Active Pharma Sciences financial results — frequently asked questions
What were Solara Active Pharma Sciences' latest quarterly results?
For the Q1 quarter (consolidated), Solara Active Pharma Sciences reported revenue of ₹250 crore, operating profit of ₹46.8 crore and net profit of ₹28.08 crore, with EPS of ₹28.79.
What is Solara Active Pharma Sciences' annual revenue and net profit?
For the financial year ended FY25, Solara Active Pharma Sciences' revenue was ₹1,092 crore and net profit ₹128 crore.
What is the EPS of Solara Active Pharma Sciences?
Quarterly EPS for Q1 was ₹28.79. Annual EPS for FY25 was ₹115.15.
Are these figures consolidated or standalone?
They are consolidated figures as reported by the company, in ₹ crore. Trailing-twelve-month and half-year columns are labelled separately and are not counted as financial years.
Same Data For Peers
- Sun Pharma Advanced Research Company Limited financial results
- SMS Pharmaceuticals Limited financial results
- Strides Pharma Science Limited financial results
- Shilpa Medicare Limited financial results
- Sun Pharmaceutical Industries Limited financial results
- Senores Pharmaceuticals Limited financial results
Trade Solara Active Pharma Sciences With ATS
Track SOLARA live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.